How Specialized Nanobodies Block Blood Clotting Proteins

A patent describing specific, tiny antibody fragments designed to bind to and inhibit Von Willebrand Factor, a protein that triggers blood clotting.

What it covers

This patent claims specific protein sequences known as Nanobodies that target Von Willebrand Factor (vWF). vWF is a protein in the blood that acts like glue, helping platelets stick together to form clots. By binding to vWF using specific amino acid sequences in their 'complementarity determining regions' (the parts of the antibody that actually grab the target), these Nanobodies prevent the protein from functioning. This effectively stops the blood from clotting in situations where it might be dangerous, such as in certain cardiovascular diseases.

What it doesn't cover

• —Does not cover general-purpose antibodies derived from traditional, large-format immune systems.
• —Does not cover Nanobodies that target proteins other than Von Willebrand Factor.
• —Does not cover amino acid sequences outside of the specific CDR combinations defined in the claims.
• —Does not cover methods of manufacturing Nanobodies that do not involve the specific sequences listed.

The clever bit

The innovation lies in the extreme smallness of the VHH domain (a single-domain antibody), which allows it to reach 'hidden' binding sites on the vWF protein that larger, traditional antibodies cannot access.

Why it matters

This technology is central to the development of Caplacizumab, a drug used to treat acquired thrombotic thrombocytopenic purpura (a rare blood disorder). By using small, stable Nanobodies instead of large antibodies, researchers created a drug that can be highly specific and potentially easier for the body to process. It represents a shift toward using 'domain antibodies' in modern medicine.

Real-world examples

• 1.Caplacizumab (Cablivi)